Loading...
Market
What will be the market share of Miplyffa in the Niemann-Pick disease type C treatment market by the end of 2025?
2
Resolution / Starting Odds
Less than 25% • 25%
25%-50% • 25%
51%-75% • 25%
More than 75% • 25%
Industry market reports and Zevra Therapeutics' official reports
Story
FDA Approves Zevra's Oral Drug Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 05:11 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, Miplyffa, as the first oral medication to treat Niemann-Pick disease, type C (NPC). This approval, announced on September 20, 2024, marks a significant milestone for the treatment of this rare and fatal genetic disorder, which affects neurons. Parents and advocates have pushed for years for treatments for NPC, facing numerous setbacks before achieving this breakthrough.
View original story
Similar markets
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Yes • 50%
No • 50%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%